1.Control of tuberculosis in the United States. American Thoracic Society. Am Rev Respir Dis 1992; 146:1623–1633.
2.Bolyard, EA, Tablan, OC, Williams, WW, Pearson, ML, Shapiro, CN, Deitchmann, SD. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1998; 19:407–463.
3.Houk, VN, Kent, DC, Sorensen, K, Baker, JH. The eradication of tuberculosis infection by isoniazid chemoprophylaxis. Arch Environ Health 1968; 16:46–50.
4.Atuk, NO, Hunt, EH. Serial tuberculin testing and isoniazid therapy in general hospital employees. JAMA 1971; 218:1795–1798.
5.Ferebee, SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 26:28–106.
6.Daniel, TM, Bowerfind, ES. Reversion of recently acquired tuberculin reactivity during isoniazid prophylaxis. Am Rev Respir Dis 1967; 95:500–502.
7.Dahlstrom, AW, Wilson, JL, Sedlacek, BB. The immediate effectiveness of isoniazid chemoprophylaxis as determined by the tuberculin test. Dis Chest 1960; 38:599–603.
8.Perez-Stable, EJ, Flaherty, D, Schecter, G, Slutkin, G, Hopewell, PC. Conversion and reversion of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1988; 137:801–804.
9.Grzybowski, S, Allen, EA. The challenge of tuberculosis in decline: a study based on the epidemiology of tuberculosis in Ontario, Canada. Am Rev Respir Dis 1964; 90:707–720.
10.Arneil, AS, McMichael, B. Effect of INH reversion rates of (very) recent converters. Can J Public Health 1974; 65:197.
11.Sepkowitz, KA. Tuberculin skin testing and the health care worker: lessons of the Prophit Survey. Tuber Lung Dis 1996; 77:81–85.
12.Wilson, LM. Reversal of the tuberculin reaction: its significance in case finding by survey skin testing. Am Rev Respir Dis 1970; 102:282–284.
13.Adams, JM, Kalajan, VA, Mork, BO, Rosenblatt, M, Rothrock, WJ, O'Loughlin, BJ. Reversal of tuberculin reaction in early tuberculosis. Dis Chest 1959; 35:348–356.
14.Robinson, A, Meyer, M, Middlebrook, G. Tuberculin hypersensitivity in tuberculous infants treated with isoniazid. N Engl J Med 1955; 252:983–985.
15.Mazurek, GH, Villarino, ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52:15–18.
16.Pottumarthy, S, Morris, AJ, Harrison, AC, Wells, VC. Evaluation of the tuberculin gamma interferon assay: potential to replace the Mantoux skin test. J Clin Microbiol 1999; 37:3229–3232.
17.Streeton, JA, Desem, N, Jones, SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998; 2:443–450.
18.Mazurek, GH, LoBue, PA, Daley, CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001;286:1740–1747.
19.Bellete, B, Coberly, J, Barnes, GL, et al. Evaluation of a whole-blood interferon γ release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis 2002; 34:1449–1456.
20.Comstock, GW, Bellete, B, Ko, C, Coberly, J, Chaisson, R, Bishai, WR. Whole-blood interferon-γ release assay versus the TST: newer not better. Clin Infect Dis 2003; 36:1207–1208.
21.Nadal, D. Is the in vitro interferon-γ release assay an adequate replacement for the tuberculin skin test? Clin Infect Dis 2002; 34:1457–1459.
22.Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999. Am J Respir Crit Care Med 2000; 161:S221–S247.
23.Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376–1395.
24.Havlir, DV, Van Der Kuyp, F, Duffy, E, Marshall, R, Horn, D, Ellner, JJ. A 19-year follow-up of tuberculin reactors: assessment of skin test reactivity and in vitro lymphocyte responses. Chest 1991; 99:1172–1176.
25.Bass, JB, Sanders, RV, Kirkpatrick, MB. Choosing an appropriate cutting point for conversion in annual tuberculin skin testing. Am Rev Respir Dis 1985; 132:379–381.
26.Bass, JB Jr. How good is the tuberculin skin test? Infect Control Hosp Epidemiol 2003; 24:797–798.
27.Marsh, BJ, San Vicente, J, von Reyn, CF. Utility of dual skin tests to evaluate tuberculin skin test reactions of 10 to 14 mm in healthcare workers. Infect Control Hosp Epidemiol 2003; 24:821–824.
28.Menzies, D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159:15–21.
29.Esser, MT, Marchese, RD, Kierstead, LS, et al. Memory T cells and vaccines. Vaccine 2003; 21:419–430.
30.Ellner, JJ. Review: the immune response in human tuberculosis—implications for tuberculosis control. J Infect Dis 1997; 176:1351–1359.
31.Smith, JA, Reichman, LB. Lymphocyte transformation: an aid in the diagnosis of tuberculosis in patients with nonreactive skin tests. Am Rev Respir Dis 1972; 106:194–201.
32.Mori, T, Sakatani, M, Yamagishi, F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170:59–64.
33.Lalvani, A. Spotting latent infection: the path to better tuberculosis control. Thorax 2003; 58:916–918.
34.Waxman, J, Lockshin, M. In vitro and in vivo cellular immunity in anergic miliary tuberculosis. Am Rev Respir Dis 1973; 107:661–664.
35.Miller, SD, Jones, HE. Correlation of lymphocyte transformation with tuberculin skin-test sensitivity. Am Rev Respir Dis 1973; 107:530–538.
36.Cox, RA, Lundberg, DI, Arnold, DR. Lymphocyte transformation assays as a diagnostic tool in tuberculosis in children. Am Rev Respir Dis 1981; 123:627–630.
37.Tager, IB, Kalaidjian, R, Baldini, L, Rocklin, RE. Variability in the intradermal and in vitro lymphocyte responses to PPD in patients receiving isoniazid chemoprophylaxis. Am Rev Respir Dis 1985; 131:214–220.